ELAN Investors Have Opportunity to Lead Elanco Animal Health Incorporated Securities Fraud Lawsuit
- 67
PR Newswire
NEW YORK, Oct. 11, 2024
NEW YORK, Oct. 11, 2024 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Elanco Animal Health Incorporated (NYSE: ELAN) between November 7, 2023 and June 26, 2024, both dates inclusive (the "Class Period"). A class action has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 6, 2024.
So what: If you purchased Elanco Animal Health Incorporated securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
What to do next: To join the Elanco Animal Health Incorporated class action, go to https://rosenlegal.com/submit-form/?case_id=29600 or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 6, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Details of the case: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Zenrelia, a once-daily oral Janus kinase ("JAK") inhibitor for canine dermatology, was less safe than Elanco had led investors to believe; (2) Elanco was unlikely to meet its own previously issued timeline for the U.S. approval and commercial launch of both Zenrelia and Credelio Quattro, a broad spectrum parasiticide product for dogs; (3) accordingly, Elanco's business and/or financial prospects were overstated; and (4) as a result, Elanco's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Elanco Animal Health Incorporated class action, go to https://rosenlegal.com/submit-form/?case_id=29600 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/elan-investors-have-opportunity-to-lead-elanco-animal-health-incorporated-securities-fraud-lawsuit-302274396.html
SOURCE THE ROSEN LAW FIRM, P. A.
PR Newswire es un distribuidor de comunicados de prensa con sede en la ciudad de Nueva York. El servicio se creó en 1954 para permitir que las empresas envíen comunicados de prensa electrónicamente a las organizaciones de noticias, al principio utilizando teleimpresores.
- GP Bullhound anuncia a los ganadores de los Premios Allstars 2024
- Xinhua Silk Road: Shanghái Xuhui celebra un evento de la industria cultural digital centrado en los nuevos avances en ecología del entretenimiento digital
- Sunwave Communications alimenta a Futurecom 2024 con soluciones inalámbricas visionarias
- Arta Finance se lanza a nivel mundial a través de Singapur, presenta Arta AI Copilot y anuncia Wealth-as-a-Service para bancos
- La FDA aprueba un nuevo tratamiento para la hemofilia A o B
- NEXTCHEM (MAIRE) RECIBIÓ UN PAQUETE DE LICENCIA Y DISEÑO DE PROCESOS PARA ACTUALIZAR LA UNIDAD DE PRODUCCIÓN DE HIDRÓGENO DE BSR EN VIETNAM, BASÁNDOSE EN TECNOLOGÍA DE PROPIEDAD PRIVADA NX REFORM™